Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by:
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT00200681
First received: September 12, 2005
Last updated: February 4, 2009
Last verified: February 2009

September 12, 2005
February 4, 2009
June 2005
January 2008   (final data collection date for primary outcome measure)
To compare the CR rate (with negative or positive immunofixation) obtained with VAD or the Velcade®/dexamethasone combination used as induction treatment in patients up to the age of 65 with newly diagnosed MM, at the end of this induction treatment
To compare the CR rate (with negative or positive immunofixation) obtained with VAD or the Velcade ® / Dexaméthasone combination used as induction treatment in patients up to the age of 65 with newly diagnosed MM, at the end of this induction treatment
Complete list of historical versions of study NCT00200681 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma
Etude Multicentrique Ouverte Randomisée de Phase III Comparant l'Association de VELCADE®-Dexaméthasone à la Chimiothérapie de Type VAD Pour le Traitement Des Patients Porteurs de Myélome Multiple de Novo Jusqu'à l'âge de 65 Ans

This is an open-label, multi-centre, randomised Phase III study, looking at a series of 480 patients up to the age of 65 with newly diagnosed multiple myeloma (MM) not previously treated. They will receive VAD or Velcade®/dexamethasone combination as induction treatment plus/minus (±) dexamethasone/cyclophosphamide/etoposide/cisplatin (DCEP) followed by autograft as first-line therapy, as the investigators try to compare the complete remission (CR) rate (with negative or positive immunofixation) at the end of their induction treatment.

After their written informed consent has been obtained and their eligibility verified, patients are randomised between 4 treatment arms: A1 VAD (4 cycles); A2 VAD (4 cycles) followed by DCEP (2 cycles); B1 Velcade® + dexamethasone (4 cycles); B2 Velcade® + dexamethasone (4 cycles) followed by DCEP (2 cycles) A1, A2, B1, B2 + autograft. Randomisation will be stratified on the basis of the initial b2 microglobulin level (> or < 3 mg/l) and the presence of chromosome 13 abnormalities identified by FISH analysis. VAD: Vincristine/Adriamycin/Dexamethasone; DCEP: Dexamethasone/Cyclophosphamide/ Etoposide/Cisplatin.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Multiple Myeloma
Drug: Velcade
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
493
June 2008
January 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Recently diagnosed MM according to the criteria of the South West Oncology Group (SWOG)
  • Not previously treated, apart from local radiotherapy, in the case of a threatening or incapacitating lesion, and/or a 4-day block of dexamethasone (40 mg/mL) in an emergency
  • Stage II or III disease according to the Durie and Salmon classification or Stage I disease with symptomatic bone lesion
  • < 65 years of age
  • Ability to give signed informed consent
  • Secretion of a measurable monoclonal spike (> 10 g/l in the serum or 0.2 g/24h in the urine)
  • Negative pregnancy test at inclusion (if necessary)
  • Absence of active infection. In the case of infection, appropriate antibiotic therapy must be administered and patients must have been apyretic for 48 hours before the start of treatment with VAD or Velcade®/dexamethasone

Exclusion Criteria:

  • ECOG performance status > 2
  • History of cancer (other than basal cell carcinoma or carcinoma of the cervix in situ)
  • Life expectancy < 2 months
  • Confirmed amyloidosis
  • Positive HIV serology
  • Serious psychiatric item in the history
  • Renal failure requiring dialysis
  • Uncontrolled diabetes, contra-indicating the use of corticosteroids
  • Peripheral neuropathy National Cancer Institute (NCI) grade > 2 (Annex 5)
  • Clinical signs of heart failure or coronary heart disease
  • Bilirubin > 3 x normal
  • Transaminases or gamma-glutamyl transpeptidase (GT) > 4 x normal
  • Platelets < 50 x 10^9/l during the 15 days prior to inclusion
  • Neutrophils < 0.75 x 10^9/l during the 15 days prior to inclusion
  • Use of an investigational medicinal product during the 30 days prior to inclusion
  • Known hypersensitivity to bortezomib, boron or mannitol
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00200681
BRD 04/11-J
Yes
Not Provided
Nantes University Hospital
Not Provided
Principal Investigator: Jean-Luc Harousseau, MD PHD Intergroupe Francophone du Myélome (IFM)
Nantes University Hospital
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP